EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Epithelial SLPI expression in severe inflammatory bowel disease relates to high IL-17 and neutrophil programming

Sandrine Nugteren, Beatriz Calado, Ytje Simons-Oosterhuis, Daniëlle H Hulleman-van Haaften, Willem K Smits, Renz Cw Klomberg, Bastiaan Tuk, Mohammed Charrout, Dicky J Lindenbergh-Kortleve, Michail Doukas, Mathijs A Sanders, Gregory van Beek und 4 weitere

JCI Insight · 2026

DOI: 10.1172/jci.insight.197126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCI Insight, 2026. Verfasst von Sandrine Nugteren und 15 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pediatrics, Division Gastroenterology and Nutrition, Erasmus University Medical Center, Rotterdam, Netherlands. Hauptthemen laut MEDLINE: Secretory Leukocyte Peptidase Inhibitor, Interleukin-17, Neutrophils, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Digestive Foundation, European Commission Horizon 2020, Stichting Dalijn.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heterogeneity in disease severity and treatment response in inflammatory bowel disease (IBD) likely evolves from individual differences in host-microbiota-immune interactions. Histological evaluation of intestinal biopsies is central to diagnosis, but histological parameters that define underlying immune mechanisms are limited. We investigated histological features that distinguish individual patient immune profiles in therapy-naive pediatric IBD patients (age 6–18 years) using biopsy immunohistochemistry and transcriptomics and plasma proteomics across two cohorts. High colonic epithelial expression of secretory leukocyte protease inhibitor (SLPI), a microbiota-induced regulator of epithelial function, occurred in IBD patients with high clinical disease activity and more severe endoscopic and microscopic disease activity. SLPI expression was related to increased neutrophil infiltration, transcriptomic signatures of activation, and genes known to associate with therapeutic resistance. High SLPI colocalized with high densities of IL-17–secreting cells and was associated with high plasma concentrations of Th17-related immune proteins. Additionally, patients with high intestinal SLPI had an intrinsically different immunotype, in which circulating neutrophils exhibited altered transcription of genes involved in neutrophil granule formation, phagocytosis, oxidative phosphorylation, and interferon signaling. Thus, high colonic SLPI expression at diagnosis associates with severe IBD, increased IL-17A–neutrophil pathway responses, and altered transcriptomic wiring of circulating neutrophils.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Secretory Leukocyte Peptidase InhibitorInterleukin-17NeutrophilsInflammatory Bowel DiseasesIntestinal MucosaHumansAdolescentFemaleChildMaleColonSeverity of Illness IndexBiopsyNeutrophil Infiltration

Stichwörter der Autor:innen

GastroenterologyImmunologyInflammatory bowel disease

Substanzen

Secretory Leukocyte Peptidase InhibitorInterleukin-17SLPI protein, humanIL17A protein, human

Autor:innen und Institutionen

  • Laboratory of Pediatrics, Division Gastroenterology and Nutrition, Erasmus University Medical Center, Rotterdam, Netherlands.
  • Department of Pediatric Gastroenterology, Sophia Children's Hospital-Erasmus University Medical Center, Rotterdam, Netherlands.
  • Delft Bioinformatics Lab, Delft University of Technology, Delft, Netherlands.
  • Department of Pathology, Erasmus University Medical Center, Rotterdam, Netherlands.
  • Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Netherlands.

Förderung

  • Dutch Digestive Foundation
  • European Commission Horizon 2020
  • Stichting Dalijn
  • Dutch Sophia Foundation
  • Top Sector Life Sciences & Health and Samenwerkende Gezondheidsfondsen
  • European Comission Horizon 2020 / Marie Skłodowska-Curie

Zitieren

APA

Nugteren, S., Calado, B., Simons-Oosterhuis, Y., Hulleman-van Haaften, D. H., Smits, W. K., Klomberg, R. C., Tuk, B., Charrout, M., Lindenbergh-Kortleve, D. J., Doukas, M., Sanders, M. A., van Beek, G., Escher, J. C., de Ridder, L., Pascutti, M. F., & Samsom, J. N. (2026). Epithelial SLPI expression in severe inflammatory bowel disease relates to high IL-17 and neutrophil programming. JCI Insight. https://doi.org/10.1172/jci.insight.197126

Vancouver

Nugteren S, Calado B, Simons-Oosterhuis Y, Hulleman-van Haaften DH, Smits WK, Klomberg RC, et al. Epithelial SLPI expression in severe inflammatory bowel disease relates to high IL-17 and neutrophil programming. JCI Insight. 2026. doi:10.1172/jci.insight.197126

BibTeX
@article{Nugteren2026,
  author = {Nugteren, Sandrine and Calado, Beatriz and Simons-Oosterhuis, Ytje and Hulleman-van Haaften, Daniëlle H and Smits, Willem K and Klomberg, Renz Cw and Tuk, Bastiaan and Charrout, Mohammed and Lindenbergh-Kortleve, Dicky J and Doukas, Michail and Sanders, Mathijs A and van Beek, Gregory and Escher, Johanna C and de Ridder, Lissy and Pascutti, Maria Fernanda and Samsom, Janneke N},
  title = {Epithelial SLPI expression in severe inflammatory bowel disease relates to high IL-17 and neutrophil programming},
  journal = {JCI Insight},
  year = {2026},
  doi = {10.1172/jci.insight.197126}
}
Kostenlos starten →